Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) and ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.
Volatility and Risk
Tandem Diabetes Care has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of -0.23, indicating that its stock price is 123% less volatile than the S&P 500.
Profitability
This table compares Tandem Diabetes Care and ENDRA Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tandem Diabetes Care | -20.17% | -68.23% | -11.07% |
| ENDRA Life Sciences | N/A | -397.71% | -190.73% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tandem Diabetes Care | $1.01 billion | 1.29 | -$204.71 million | ($3.07) | -6.25 |
| ENDRA Life Sciences | N/A | N/A | -$7.03 million | ($8.92) | -0.55 |
ENDRA Life Sciences has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Tandem Diabetes Care and ENDRA Life Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tandem Diabetes Care | 1 | 9 | 8 | 1 | 2.47 |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
Tandem Diabetes Care currently has a consensus price target of $29.06, indicating a potential upside of 51.49%. ENDRA Life Sciences has a consensus price target of $30.00, indicating a potential upside of 507.29%. Given ENDRA Life Sciences’ higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Tandem Diabetes Care.
Insider & Institutional Ownership
1.2% of ENDRA Life Sciences shares are held by institutional investors. 1.9% of Tandem Diabetes Care shares are held by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Tandem Diabetes Care beats ENDRA Life Sciences on 8 of the 14 factors compared between the two stocks.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
